NCT06285240View on ClinicalTrials.gov

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 28, 2024

Primary Completion Date

September 23, 2024

Study Completion Date

September 23, 2024

Conditions

Alzheimer's Disease

Interventions

DRUG

MK-1167

1 mg and 5 mg oral capsules

DRUG

Donepezil

10 mg oral tablets

DRUG

Placebo

MK-1167 matching placebo administered oral capsules

Trial Locations (3)

30030

CenExel iResearch, LLC ( Site 0003), Decatur

31405

CenExel iResearch, LLC ( Site 0004), Savannah

33009

Velocity Clinical Research, Hallandale Beach ( Site 0001), Hallandale

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT06285240 - Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007) | Biotech Hunter | Biotech Hunter